ACE-031

What it is

ACE-031 is not a small peptide in the usual sense. It is a engineered fusion protein: the outer part of the activin receptor type IIB joined to the tail of an antibody (IgG Fc). It acts as a decoy that soaks up myostatin and related signalling proteins that normally put a brake on muscle growth.

It was developed by Acceleron Pharma (later in partnership with Shire) for muscle-wasting conditions such as Duchenne muscular dystrophy. The company stopped the programme in 2011-2012 after safety problems appeared in the clinical trials. It has never been approved anywhere, and any ACE-031 sold today is an unlicensed research chemical.

It is on this site because people ask about it, and the honest answer is that it is one of the clearer examples of a compound that looked exciting and then showed real harm in people.

History

Developed by Acceleron in the late 2000s. Early trials in healthy postmenopausal women showed increases in lean muscle mass. A Phase 2 trial in boys with Duchenne muscular dystrophy was halted around 2010-2011 after some participants had nosebleeds, bleeding gums and dilated small blood vessels on the skin (telangiectasia). The programme was discontinued. Treat the finer details of the dates and trial sizes as something to check against primary sources.

How it works

Myostatin is a protein that limits how much muscle you build. ACE-031 mops up myostatin and several related proteins (including activins and GDF11) before they reach their receptor, which in animals and early human data led to more muscle. The problem is the same blockade also affects other tissues. Activin and GDF-family signalling matters for blood vessel maintenance, which is the leading explanation for the bleeding seen in trials.

Dosage

• There is no safe or established dose. The clinical trial doses were calculated per kilogram of body weight and given every few weeks under medical monitoring, and that research was stopped.
• Community-reported doses are guesses scaled from trial data and animal work. Because of the long half-life, effects and side effects persist for a long time after a single injection, so you cannot easily stop it once something goes wrong.
• This site does not recommend a dose.

How it is taken

• In trials it was given as a subcutaneous injection every few weeks.
• A 29-31G insulin syringe into belly fat is the route people use outside trials.

How to reconstitute

• For a 1 mg vial, adding 1 ml of bacteriostatic water gives 1 mg/ml. On a 1 ml (100-unit) insulin syringe, 10 units (0.1 ml) is 0.1 mg and 50 units is 0.5 mg.
• Add water slowly down the inside wall of the vial, swirl gently and do not shake. Large fusion proteins are more fragile than short peptides and can clump or lose activity if handled roughly.
• A 1 mg vial is a very small amount for a protein like this. Many products sold under this name will be under-dosed or something else entirely.

How it should arrive

A sealed glass vial with a small white to off-white powder cake. Because the genuine drug is a large protein, grey-market vials are very hard to verify without third-party mass spectrometry.

How it should look once reconstituted

A clear, colourless solution. Cloudiness, stringy particles or foaming suggest damaged protein and the vial should not be used.

What to expect, and when

• In the healthy-volunteer trial, increases in lean mass were measurable within weeks of dosing.
• Bleeding-type side effects in trials appeared during the dosing period, not years later.
• There is no meaningful human timeline data beyond those short studies.

Side effects

• Nosebleeds and bleeding gums, the issue that led trial investigators to stop.
• Small dilated blood vessels visible on the skin (telangiectasia).
• Injection-site reactions such as redness, pain or swelling.
• Acne-like skin changes were reported in some participants. Check primary sources for details.

Risks

• Trials were halted for safety. This is not a case of a drug being shelved for commercial reasons.
• Blocking activin and related signalling may affect blood vessels, the reproductive system and other tissues in ways that are not fully mapped.
• The long half-life means you cannot stop effects quickly.
• There is no safe human dose and nobody is monitoring grey-market users the way trial doctors did.
• Immune reactions to a foreign protein are possible, and repeat exposure raises that risk.
• Heart and vascular effects of blocking this pathway over the long term are unknown.
• Quality is unverifiable. A protein this complex is far harder to make correctly than a short peptide.

Potential gains

• In controlled trials, lean muscle mass increased in healthy volunteers.
• In animal models of muscle wasting, it increased muscle size and strength.
• There was no clear functional benefit shown in the Duchenne trial before it was stopped, and no data supports it for healthy lifters.

Other useful information

If your goal is muscle or recovery, there are options with an actual human safety record, such as training, sleep, protein and (under medical supervision) licensed treatments. ACE-031 is the compound most often cited as a reason for caution about myostatin blockers in general. Related drugs (follistatin-type approaches) are worth reading about separately and carry their own uncertainties.